BridgeBio Pharma (BBIO) Stock Forecast & Price Target

Compare

1,449 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BBIO Analyst Ratings

Strong Buy

17 Buy

0 Hold

0 Sell

Based on 17 analysts giving stock ratings to

BridgeBio

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BBIO Stock 12 Month Forecast

Average Price Target

$103.00

▲(57.59% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is $103.00 with a high forecast of $157.00 and a low forecast of $81.00. The average price target represents a 57.59% change from the last price of $65.36.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","95":"$95","158":"$158","63.5":"$63.5","126.5":"$126.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":157,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$157.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$103.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":81,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$81.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,63.5,95,126.5,158],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.5,72.53846153846153,79.57692307692308,86.61538461538461,93.65384615384616,100.6923076923077,107.73076923076923,114.76923076923077,121.8076923076923,128.84615384615384,135.8846153846154,142.9230769230769,149.96153846153845,{"y":157,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.5,68.38461538461539,71.26923076923077,74.15384615384616,77.03846153846153,79.92307692307692,82.8076923076923,85.6923076923077,88.57692307692308,91.46153846153845,94.34615384615384,97.23076923076923,100.11538461538461,{"y":103,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.5,66.6923076923077,67.88461538461539,69.07692307692308,70.26923076923077,71.46153846153847,72.65384615384616,73.84615384615384,75.03846153846153,76.23076923076923,77.42307692307692,78.61538461538461,79.8076923076923,{"y":81,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.37,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.49,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.24,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$157.00

Average Price Target$103.00

Lowest Price Target$81.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ram Selvaraju

H.C. Wainwright

$100

Buy

53.00%

Upside

Reiterated

03/09/26

BridgeBio Pharma: Advancing Late-Stage Pipeline and Near-Term Catalysts Underpin Reaffirmed Buy and $100 Target

Tyler Van Buren

TD Cowen

$95

Buy

45.35%

Upside

Reiterated

02/25/26

BridgeBio: Robust Attruby Launch and Late-Stage Pipeline Support Buy Rating and Path to Sustainable Cash Generation

Cory Kasimov

Evercore ISI

$100→$125

Buy

91.25%

Upside

Reiterated

02/25/26

BridgeBio price target raised to $125 from $100 at Evercore ISIBridgeBio price target raised to $125 from $100 at Evercore ISI

Joshua Schimmer

Cantor Fitzgerald

$110

Buy

68.30%

Upside

Reiterated

02/25/26

BridgeBio Pharma (BBIO) Gets a Buy from Cantor Fitzgerald

Jason Zemansky

Bank of America Securities

$95

Buy

45.35%

Upside

Reiterated

02/25/26

BridgeBio Pharma: Clear Path to 2027 Profitability with Underappreciated Pipeline Upside

Andrew Tsai

Jefferies

$100

Buy

53.00%

Upside

Reiterated

02/25/26

BridgeBio Pharma (BBIO) Gets a Buy from Jefferies

Trevor Allred

Oppenheimer

$83→$81

Buy

23.93%

Upside

Reiterated

02/25/26

BridgeBio Pharma (BBIO) Receives a Buy from Oppenheimer

Danielle Brill

Truist Financial

$86→$95

Buy

45.35%

Upside

Reiterated

02/25/26

Analysts Conflicted on These Healthcare Names: Day One Biopharmaceuticals (NASDAQ: DAWN), Fresenius Medical Care (NYSE: FMS) and BridgeBio Pharma (NASDAQ: BBIO)

Sean Laaman

Morgan Stanley

$96→$98

Buy

49.94%

Upside

Reiterated

02/25/26

Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (NASDAQ: TEM), BridgeBio Pharma (NASDAQ: BBIO) and Establishment Labs Holdings (NASDAQ: ESTA)

Biren Amin

Piper Sandler

$98→$111

Buy

69.83%

Upside

Reiterated

02/25/26

Piper Sandler Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

Eliana Merle

Barclays

$157

Buy

140.21%

Upside

Reiterated

02/25/26

Barclays Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

Derek Archila

Wells Fargo

$88→$98

Buy

49.94%

Upside

Reiterated

02/13/26

Analysts Are Bullish on Top Healthcare Stocks: PolyPid (PYPD), Dexcom (DXCM)

Paul Choi

Goldman Sachs

$100→$112

Buy

71.36%

Upside

Reiterated

02/13/26

Analysts Offer Insights on Healthcare Companies: Urogen Pharma (NASDAQ: URGN), Karyopharm Therapeutics (NASDAQ: KPTI) and BridgeBio Pharma (NASDAQ: BBIO)

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

02/12/26

BridgeBio (BBIO): Buy Rating Supported by Strong Phase 3 Infigratinib Data in Achondroplasia and Growing Commercial Momentum

William Pickering

Bernstein

$100

Buy

53.00%

Upside

Assigned

02/12/26

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE), American Well (NYSE: AMWL) and BridgeBio Pharma (NASDAQ: BBIO)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ram Selvaraju

H.C. Wainwright

$100

Buy

53.00%

Upside

Reiterated

03/09/26

BridgeBio Pharma: Advancing Late-Stage Pipeline and Near-Term Catalysts Underpin Reaffirmed Buy and $100 Target

Tyler Van Buren

TD Cowen

$95

Buy

45.35%

Upside

Reiterated

02/25/26

BridgeBio: Robust Attruby Launch and Late-Stage Pipeline Support Buy Rating and Path to Sustainable Cash Generation

Cory Kasimov

Evercore ISI

$100→$125

Buy

91.25%

Upside

Reiterated

02/25/26

BridgeBio price target raised to $125 from $100 at Evercore ISIBridgeBio price target raised to $125 from $100 at Evercore ISI

Joshua Schimmer

Cantor Fitzgerald

$110

Buy

68.30%

Upside

Reiterated

02/25/26

BridgeBio Pharma (BBIO) Gets a Buy from Cantor Fitzgerald

Jason Zemansky

Bank of America Securities

$95

Buy

45.35%

Upside

Reiterated

02/25/26

BridgeBio Pharma: Clear Path to 2027 Profitability with Underappreciated Pipeline Upside

Andrew Tsai

Jefferies

$100

Buy

53.00%

Upside

Reiterated

02/25/26

BridgeBio Pharma (BBIO) Gets a Buy from Jefferies

Trevor Allred

Oppenheimer

$83→$81

Buy

23.93%

Upside

Reiterated

02/25/26

BridgeBio Pharma (BBIO) Receives a Buy from Oppenheimer

Danielle Brill

Truist Financial

$86→$95

Buy

45.35%

Upside

Reiterated

02/25/26

Analysts Conflicted on These Healthcare Names: Day One Biopharmaceuticals (NASDAQ: DAWN), Fresenius Medical Care (NYSE: FMS) and BridgeBio Pharma (NASDAQ: BBIO)

Sean Laaman

Morgan Stanley

$96→$98

Buy

49.94%

Upside

Reiterated

02/25/26

Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (NASDAQ: TEM), BridgeBio Pharma (NASDAQ: BBIO) and Establishment Labs Holdings (NASDAQ: ESTA)

Biren Amin

Piper Sandler

$98→$111

Buy

69.83%

Upside

Reiterated

02/25/26

Piper Sandler Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

Eliana Merle

Barclays

$157

Buy

140.21%

Upside

Reiterated

02/25/26

Barclays Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

Derek Archila

Wells Fargo

$88→$98

Buy

49.94%

Upside

Reiterated

02/13/26

Analysts Are Bullish on Top Healthcare Stocks: PolyPid (PYPD), Dexcom (DXCM)

Paul Choi

Goldman Sachs

$100→$112

Buy

71.36%

Upside

Reiterated

02/13/26

Analysts Offer Insights on Healthcare Companies: Urogen Pharma (NASDAQ: URGN), Karyopharm Therapeutics (NASDAQ: KPTI) and BridgeBio Pharma (NASDAQ: BBIO)

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

02/12/26

BridgeBio (BBIO): Buy Rating Supported by Strong Phase 3 Infigratinib Data in Achondroplasia and Growing Commercial Momentum

William Pickering

Bernstein

$100

Buy

53.00%

Upside

Assigned

02/12/26

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE), American Well (NYSE: AMWL) and BridgeBio Pharma (NASDAQ: BBIO)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BridgeBio Pharma

3 Months

xxx

Success Rate

14/16 ratings generated profit

Average Return

+29.51%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 87.50% of your transactions generating a profit, with an average return of +29.51% per trade.

1 Year

Jason ZemanskyBank of America Securities

Success Rate

15/17 ratings generated profit

Average Return

+64.91%

a rating ―

Copying Jason Zemansky's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +64.91% per trade.

2 Years

xxx

Success Rate

16/16 ratings generated profit

Average Return

+113.49%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +113.49% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BBIO Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BBIO has received 43 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BBIO average Analyst price target in the past 3 months is 103.00.

Each month's total comprises the sum of three months' worth of ratings.

BBIO Financial Forecast

BBIO Earnings Forecast

Next quarter’s earnings estimate for BBIO is -$0.65 with a range of -$0.87 to -$0.49. The previous quarter’s EPS was -$1.00. BBIO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year BBIO has Performed in-line its overall industry.

BBIO Sales Forecast

Next quarter’s sales forecast for BBIO is $180.70M with a range of $167.80M to $194.70M. The previous quarter’s sales results were $154.18M. BBIO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year BBIO has Performed in-line its overall industry.

BBIO Stock Forecast FAQ

What is BBIO’s average 12-month price target, according to analysts?

Based on analyst ratings, BridgeBio Pharma Inc’s 12-month average price target is 103.00.

What is BBIO’s upside potential, based on the analysts’ average price target?

BridgeBio Pharma Inc has 57.59% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BBIO a Buy, Sell or Hold?

BridgeBio Pharma Inc has a consensus rating of Strong Buy which is based on 17 buy ratings, 0 hold ratings and 0 sell ratings.

What is BridgeBio Pharma Inc’s price target?

The average price target for BridgeBio Pharma Inc is 103.00. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $157.00 ,the lowest forecast is $81.00. The average price target represents 57.59% Increase from the current price of $65.36.

What do analysts say about BridgeBio Pharma Inc?

BridgeBio Pharma Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of BBIO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

BridgeBio Pharma (BBIO) Stock Forecast & Price Target

BBIO Analyst Ratings

BBIO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BridgeBio Pharma

BBIO Analyst Recommendation Trends

BBIO Financial Forecast

BBIO Earnings Forecast

BBIO Sales Forecast

BBIO Stock Forecast FAQ

Detailed List of Analyst Forecasts